MCID: PRK031
MIFTS: 51

Parkinson Disease 1

Categories: Genetic diseases, Neuronal diseases, Mental diseases, Rare diseases, Metabolic diseases

Aliases & Classifications for Parkinson Disease 1

MalaCards integrated aliases for Parkinson Disease 1:

Name: Parkinson Disease 1 54 29 13
Parkinson Disease 1, Autosomal Dominant 71 69
Atypical Parkinson Disease 71 69
Autosomal Dominant Parkinson Disease 1 12
Parkinson Disease Autosomal Dominant 1 71
Parkinson Disease, Familial, Type 1 69
Parkinson Disease Familial Type 1 71
Lewy Body Parkinsonism 71
Park1 71

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant

Miscellaneous:
progressive disorder
onset mid to late adulthood
insidious onset
levodopa-responsive


HPO:

32
parkinson disease 1:
Onset and clinical course insidious onset progressive
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Parkinson Disease 1

UniProtKB/Swiss-Prot : 71 Parkinson disease 1, autosomal dominant: A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

MalaCards based summary : Parkinson Disease 1, also known as parkinson disease 1, autosomal dominant, is related to parkinson disease, late-onset and parkinson disease 4, and has symptoms including dysphagia, dystonia and myoclonus. An important gene associated with Parkinson Disease 1 is SNCA (Synuclein Alpha), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Amphetamine addiction. The drugs Rasagiline and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, subthalamic nucleus and testes, and related phenotype is taste/olfaction.

Disease Ontology : 12 A Parkinson's disease that has material basis in mutation in the alpha-synuclein (SNCA) gene on chromosome 4q22.1.

OMIM : 54
Parkinson disease is the second most common neurogenic disorder after Alzheimer disease (AD; 104300), affecting approximately 1% of the population over age 50. Clinical manifestations include resting tremor, muscular rigidity, bradykinesia, and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia (Polymeropoulos et al., 1996). For a general phenotypic description and a discussion of genetic heterogeneity of Parkinson disease, see 168600. (168601)

Related Diseases for Parkinson Disease 1

Diseases in the Parkinson Disease, Late-Onset family:

Parkinson Disease 7, Autosomal Recessive Early-Onset Parkinson Disease 6, Early Onset
Parkinson Disease 19a, Juvenile-Onset Parkinson Disease 10
Parkinson Disease 16 Parkinson Disease 13
Parkinson Disease 11 Parkinson Disease 21
Parkinson Disease 18 Parkinson Disease 5
Parkinson Disease 4 Parkinson Disease 1
Parkinson Disease, Juvenile, Type 2 Parkinson Disease 22, Autosomal Dominant
Parkinson Disease 8 Parkinson Disease 23, Autosomal Recessive, Early Onset
Parkinson Disease 17 Parkinson Disease 20, Early-Onset
Parkinson Disease 15, Autosomal Recessive Parkinson Disease 14, Autosomal Recessive
Parkinson Disease 12 Juvenile-Onset Parkinson Disease
Early-Onset Parkinson Disease Lrrk2-Related Parkinson Disease
Vps35-Related Parkinson Disease Parkinson Disease Type 3
Parkinson Disease Type 9 Synj1-Related Parkinson Disease
Dnajc6-Related Parkinson Disease Eif4g1-Related Parkinson Disease
Fbxo7-Related Parkinson Disease Gigyf2-Related Parkinson Disease
Htra2-Related Parkinson Disease Park7-Related Parkinson Disease
Pla2g6-Related Parkinson Disease Snca-Related Parkinson Disease
Hereditary Late-Onset Parkinson Disease

Diseases related to Parkinson Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 25)
id Related Disease Score Top Affiliating Genes
1 parkinson disease, late-onset 30.4 SLC18A2 SLC6A3 SNCA
2 parkinson disease 4 11.3
3 snca-related parkinson disease 11.1
4 kufor-rakeb syndrome 10.9
5 sebaceous gland disease 10.0 SLC6A3 SNCA
6 supranuclear palsy, progressive atypical 10.0 SLC6A3 SNCA
7 thyrotropin-releasing hormone deficiency 9.9 SLC6A3 SNCA
8 proteus syndrome, somatic 9.9 SLC6A3 SNCA
9 parietal foramina 3 9.9 SLC6A3 SNCA
10 personality disorder 9.9 SLC6A3 SNCA
11 prostate carcinoma in situ 9.8 SLC6A3 SNCA
12 contact dermatitis 9.8 SLC18A2 SLC6A3
13 dementia, lewy body 9.7
14 dementia 9.7
15 chronic conjunctivitis 9.6 SLC18A2 SLC6A3
16 hepatopulmonary syndrome 9.5 SLC18A2 SLC6A3
17 epileptic encephalopathy, early infantile, 45 9.4 SLC18A2 SLC6A3
18 microcephaly 18, primary, autosomal dominant 9.2 SLC18A2 SLC6A3 SNCA
19 bladder hepatoid adenocarcinoma 9.2 SLC18A2 SLC6A3 SNCA
20 perry syndrome 9.2 SLC18A2 SLC6A3 SNCA
21 craniosynostosis, adelaide type 9.2 SLC18A2 SLC6A3
22 ovarian cystadenocarcinoma 9.2 SLC18A2 SLC6A3 SNCA
23 ganglioneuroma 9.2 SLC18A2 SLC6A3 SNCA
24 adrenal gland pheochromocytoma 9.2 SLC18A2 SLC6A3 SNCA
25 hepatic angiomyolipoma 9.2 SLC18A2 SLC6A3 SNCA

Graphical network of the top 20 diseases related to Parkinson Disease 1:



Diseases related to Parkinson Disease 1

Symptoms & Phenotypes for Parkinson Disease 1

Symptoms via clinical synopsis from OMIM:

54

Abdomen- Gastroin testinal:
dysphagia

Head And Neck- Face:
masked facies

Genitourinary- Bladder:
urinary urgency

Neurologic- Central Nervous System:
dystonia
myoclonus
dysarthria
sleep disturbances
parkinsonism
more
Neurologic- Behavioral Psychiatric Manifestations:
depression


Clinical features from OMIM:

168601

Human phenotypes related to Parkinson Disease 1:

32 (show all 15)
id Description HPO Frequency HPO Source Accession
1 dysphagia 32 HP:0002015
2 dystonia 32 HP:0001332
3 myoclonus 32 HP:0001336
4 dysarthria 32 HP:0001260
5 parkinsonism 32 HP:0001300
6 bradykinesia 32 HP:0002067
7 rigidity 32 HP:0002063
8 shuffling gait 32 HP:0002362
9 postural instability 32 HP:0002172
10 depression 32 HP:0000716
11 urinary urgency 32 HP:0000012
12 hypokinesia 32 HP:0002375
13 resting tremor 32 HP:0002322
14 mental deterioration 32 HP:0001268
15 sleep disturbance 32 HP:0002360

UMLS symptoms related to Parkinson Disease 1:


muscle rigidity, myoclonus, sleep disturbances, bradykinesia

MGI Mouse Phenotypes related to Parkinson Disease 1:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 taste/olfaction MP:0005394 8.8 SLC18A2 SLC6A3 SNCA

Drugs & Therapeutics for Parkinson Disease 1

Drugs for Parkinson Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 416)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rasagiline Approved Phase 4,Phase 3,Phase 1 136236-51-6 3052776
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Pramipexole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104632-26-0 59868 119570
4
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 91374-20-8, 91374-21-9 5095 497540
5
Donepezil Approved Phase 4,Phase 2,Phase 1 120014-06-4 3152
6
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-92-7 6047
7
Amantadine Approved Phase 4,Phase 3,Phase 2,Phase 1 768-94-5 2130
8
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Carbidopa Approved Phase 4,Phase 3,Phase 2,Phase 1 28860-95-9 34359 38101
11
Midodrine Approved Phase 4,Phase 1 133163-28-7, 42794-76-3 4195
12 Piracetam Approved Phase 4,Phase 2 7491-74-9
13
Norepinephrine Approved Phase 4,Phase 1,Phase 2 51-41-2 439260
14
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
15
Entacapone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130929-57-6 5281081
16
Methylphenidate Approved, Investigational Phase 4,Early Phase 1 113-45-1 4158
17
Apomorphine Approved, Investigational Phase 4,Phase 3,Phase 2 41372-20-7, 58-00-4 6005
18
Trimethobenzamide Approved Phase 4,Phase 1 138-56-7 5577
19
Memantine Approved, Investigational Phase 4 19982-08-2 4054
20
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
21
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
22
Bromocriptine Approved, Investigational Phase 4,Phase 3,Phase 2 25614-03-3 31101
23
Cabergoline Approved Phase 4,Phase 3 81409-90-7 54746
24
Armodafinil Approved, Investigational Phase 4,Phase 2,Early Phase 1 112111-43-0
25
Modafinil Approved, Investigational Phase 4,Phase 2,Early Phase 1 68693-11-8 4236
26
Droxidopa Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 23651-95-8 443940
27
Rivastigmine Approved, Investigational Phase 4,Phase 3 123441-03-2 77991
28
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
29
Suvorexant Approved Phase 4 1030377-33-3
30 Mirabegron Approved Phase 4 223673-61-8
31
Varenicline Approved, Investigational Phase 4,Phase 2 249296-44-4 5310966
32
Amitriptyline Approved Phase 4 50-48-6 2160
33
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
34
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
35
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
36
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
37
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
38
Propranolol Approved, Investigational Phase 4 525-66-6 4946
39
Rizatriptan Approved Phase 4 145202-66-0, 144034-80-0 5078
40
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
41
Topiramate Approved Phase 4 97240-79-4 5284627
42
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
43
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
44
Glutamic Acid Approved, Nutraceutical Phase 4,Phase 2 56-86-0 33032
45
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 2 67-97-0 6221 10883523 5280795
46
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
47
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
48
Clopidogrel Approved, Nutraceutical Phase 4 120202-66-6, 113665-84-2 60606
49 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
50
Imidazole Experimental Phase 4 288-32-4 795

Interventional clinical trials:

(show top 50) (show all 995)

id Name Status NCT ID Phase Drugs
1 Emotion, Mood and Executive Function in Parkinson`s Disease (PD) Unknown status NCT01385735 Phase 4 Rasagiline;Placebo
2 The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease Unknown status NCT00696215 Phase 4 placebo;rasagiline
3 A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients Unknown status NCT01007630 Phase 4 Rasagiline;Placebo
4 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study Unknown status NCT01765257 Phase 4 AZILECT®;Placebo
5 Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) Unknown status NCT01515774 Phase 4 Mirapex ER
6 The Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4 Donepezil
7 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients Unknown status NCT01780467 Phase 4
8 The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy Unknown status NCT01313819 Phase 4 PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj
9 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
10 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain Completed NCT01744496 Phase 4 Rotigotine;Placebo
11 Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy Completed NCT01782222 Phase 4 Rotigotine
12 Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease Completed NCT01723228 Phase 4 Rasagiline;Placebo
13 Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease Completed NCT00437125 Phase 4 Duloxetine hydrochloride
14 Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease Completed NCT01049984 Phase 4 Rasagiline;Placebo
15 Olfaction in Patients With Parkinson's Disease Following Treatment With Rasagiline Completed NCT00902941 Phase 4 Azilect 1mg;Placebo
16 A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery Completed NCT00594464 Phase 4 Rotigotine
17 D-serine Adjuvant Treatment for Parkinson's Disease Completed NCT00215904 Phase 4 D-serine (~2g/day)
18 Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity Measured Through Implanted Stimulators Completed NCT02256319 Phase 4 Dexmedetomidine;Propofol
19 Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms Completed NCT00297778 Phase 4 Pramipexole
20 A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy Completed NCT01497652 Phase 4 Rasagiline/Placebo;Rasagiline
21 A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease Completed NCT01711866 Phase 4 Rotigotine
22 Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors Completed NCT00906828 Phase 4 levodopa/carbidopa;entacapone;tolcapone
23 Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II) Completed NCT00914095 Phase 4 methylphenidate;placebo
24 Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychometric Properties Completed NCT00932581 Phase 4
25 Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease Completed NCT01313845 Phase 4 amantadine sulfate;0.9% sodium chloride
26 Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease Completed NCT01168596 Phase 4 Rasagiline;Placebo
27 The Effect of Rasagiline on Cognition in Parkinson's Disease Completed NCT01382342 Phase 4 Rasagiline;Placebo
28 Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment Completed NCT00489255 Phase 4 Tigan®;Placebo
29 Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's Disease Completed NCT01108029 Phase 4 memantine;placebo
30 Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease Completed NCT00526630 Phase 4 Methylphenidate (MPD);Placebo
31 Profile of Depressive Symptoms in Parkinsons Disease Completed NCT00349310 Phase 4 Pramipexole
32 Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients Completed NCT01523301 Phase 4 Rotigotine;Placebo
33 Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms Completed NCT01300819 Phase 4 Rotigotine
34 Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists Completed NCT00443872 Phase 4 orally disintegrating selegiline (Zelapar)
35 Study to Evaluate Initiation of Stalevo in Early Wearing-off Completed NCT00462007 Phase 4 Stalevo
36 Levodopa Benserazide Generic Formulation Versus the Originator Completed NCT02741947 Phase 4 Levodopa Benserazide Madopar;Levodopa Benserazide Teva Italia
37 Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease Completed NCT00646204 Phase 4 Memantine;placebo
38 Dopaminergic Modulation of Declarative Memory Completed NCT03151460 Phase 4 Dopamine Agent
39 Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) Completed NCT01770145 Phase 4 APOKYN;L-dopa;Trimethobenzamide
40 Donepezil to Treat Dementia in Parkinson's Disease Completed NCT00030979 Phase 4 Donepezil
41 Stalevo in Early Wearing-Off Patients Completed NCT00125567 Phase 4 Stalevo (levodopa/carbidopa/entacapone);Levodopa/carbidopa
42 Motor Response to Sildenafil in PD Completed NCT01941732 Phase 4 Sildenafil
43 A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease Completed NCT00399477 Phase 4 rasagiline mesylate;Rasagiline mesylate plus Mirapex;Rasagiline mesylate with Levodopa;Rasagiline mesylate with Requip
44 Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease Completed NCT01032486 Phase 4 Rasagiline mesylate
45 Rasagiline and Apathy in Parkinson's Disease Completed NCT00755027 Phase 4 Rasagiline
46 Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease Completed NCT00095810 Phase 4 aripiprazole
47 Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK) Completed NCT00632762 Phase 4 mantadix
48 Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease Completed NCT00219284 Phase 4 Carbidopa/levodopa/entacapone
49 Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease Completed NCT01662414 Phase 4
50 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease Completed NCT01421719 Phase 4 Cystoscopic injection of Botox into the urinary bladder

Search NIH Clinical Center for Parkinson Disease 1

Genetic Tests for Parkinson Disease 1

Genetic tests related to Parkinson Disease 1:

id Genetic test Affiliating Genes
1 Parkinson Disease 1 29

Anatomical Context for Parkinson Disease 1

MalaCards organs/tissues related to Parkinson Disease 1:

39
Brain, Subthalamic Nucleus, Testes, Bone, Cortex, Heart, Spinal Cord

Publications for Parkinson Disease 1

Variations for Parkinson Disease 1

UniProtKB/Swiss-Prot genetic disease variations for Parkinson Disease 1:

71
id Symbol AA change Variation ID SNP ID
1 SNCA p.Ala53Thr VAR_007454 rs104893877
2 SNCA p.Ala30Pro VAR_007957 rs104893878
3 SNCA p.Glu46Lys VAR_022703 rs104893875
4 SNCA p.His50Gln VAR_070171 rs201106962

ClinVar genetic disease variations for Parkinson Disease 1:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 SNCA NM_000345.3(SNCA): c.157G> A (p.Ala53Thr) single nucleotide variant Pathogenic rs104893877 GRCh37 Chromosome 4, 90749300: 90749300
2 SNCA NM_000345.3(SNCA): c.88G> C (p.Ala30Pro) single nucleotide variant Pathogenic rs104893878 GRCh37 Chromosome 4, 90756731: 90756731
3 SNCA SNCA, DUPLICATION duplication Pathogenic
4 SNCA NM_000345.3(SNCA): c.152G> A (p.Gly51Asp) single nucleotide variant Pathogenic rs431905511 GRCh37 Chromosome 4, 90749305: 90749305

Expression for Parkinson Disease 1

Search GEO for disease gene expression data for Parkinson Disease 1.

Pathways for Parkinson Disease 1

GO Terms for Parkinson Disease 1

Cellular components related to Parkinson Disease 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.16 SLC6A3 SNCA
2 cytoplasmic vesicle membrane GO:0030659 8.96 SLC18A2 SNCA
3 synaptic vesicle GO:0008021 8.62 SLC18A2 SNCA

Biological processes related to Parkinson Disease 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.48 SLC6A3 SNCA
2 chemical synaptic transmission GO:0007268 9.46 SLC18A2 SNCA
3 aging GO:0007568 9.43 SLC6A3 SNCA
4 locomotory behavior GO:0007626 9.4 SLC18A2 SLC6A3
5 neurotransmitter transport GO:0006836 9.37 SLC18A2 SLC6A3
6 response to cocaine GO:0042220 9.32 SLC6A3 SNCA
7 dopamine biosynthetic process GO:0042416 9.26 SLC6A3 SNCA
8 monoamine transport GO:0015844 9.16 SLC18A2 SLC6A3
9 dopamine transport GO:0015872 8.96 SLC18A2 SLC6A3
10 dopamine uptake involved in synaptic transmission GO:0051583 8.62 SLC6A3 SNCA

Molecular functions related to Parkinson Disease 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein N-terminus binding GO:0047485 8.96 SLC6A3 SNCA
2 monoamine transmembrane transporter activity GO:0008504 8.62 SLC18A2 SLC6A3

Sources for Parkinson Disease 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....